Patheon Achieved More Outsourced New Drug Approvals Than Any Other Provider According to 2017 PharmSource CMO Scorecard
30 March 2017 - 9:30PM
Business Wire
Company “dominated” latest industry report with
approximately 30 percent of all outsourced approvals, four times
more than the nearest competitor
Patheon N.V. (NYSE: PTHN), a leading global provider of
high-quality drug development and delivery solutions to the
pharmaceutical sector, has been cited once again as capturing the
most outsourced new drug approvals (NDAs) in the US than any other
contract manufacturing organization (CMO) in 2016. NDAs are
authorized by the U.S. Food and Drug Administration (FDA).
The annual 2017 PharmSource CMO Scorecard underscores the
company’s leadership position in the CMO sector highlighting the
fact that Patheon is supporting approximately 30 percent of all new
drug approvals on behalf of clients in 2016 and has been awarded
approximately 25 percent of all outsourced approvals in the last
decade (2007-2016).
“Patheon continues to bring expertise, value and a solid track
record in navigating the regulatory needs of clients, resulting in
the company gaining a dominant share of product approvals in 2016
and over the last 10 years,” said Michael Lehmann, president,
global sales and marketing. “Securing market approval is key to
pharma companies’ success and Patheon has the experience navigating
the path to a regulatory approval.”
Key findings of the report include Patheon receiving:
- 17 out of 55 (30 percent) of all
outsourced NDA approvals in 2016, four times more than the closest
competitor
- 112 new molecular entity (NME) and
non-NME NDA approvals, more than the next six leading CMOs combined
(2007-2016)
- Significant awards for solid dose NME
approvals, solid dose non-NME approvals and parenteral NME
approvals in the last ten years.
Patheon was the only CMO recognized for having multiple
approvals for both drug substance and drug product.
The annual CMO Scorecard analyzes the CMO industry, using NDA
approvals as a key indicator of performance, with data compiled
from a broad array of public sources including regulatory and
financial filings, and press releases.
About Patheon
Patheon is a leading global provider of pharmaceutical
development and manufacturing services. With approximately 9,100
employees and contractors worldwide, Patheon provides a
comprehensive, integrated and highly customizable set of solutions
to help clients of all sizes satisfy complex development and
manufacturing needs at any stage of the pharmaceutical development
cycle. A Healthier World. Delivered.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170330005104/en/
Patheon N.V.Mari Mansfield, +1-919-226-3137Senior Director,
External
CommunicationsMari.Mansfield@Patheon.commedia@patheon.com
PATHEON N.V. (NYSE:PTHN)
Historical Stock Chart
From Jun 2024 to Jul 2024
PATHEON N.V. (NYSE:PTHN)
Historical Stock Chart
From Jul 2023 to Jul 2024